annual

EskoArtwork the worldwide market leader with pre-production and collaboration software for packaging buyers designers and manufacturers is to direct its annual seminar for packaging professionals on the 29th November from 10am – 4.45pm. It has been a work year in the Packaging Industry especially for Esko and Artwork Systems as they merged into one organization with one vision. Around 150 packaging companies have accepted the invitation to be this popular event held this year at Nottingham University’s Conference Centre. Guido Van der Schueren. Chief Commercial Officer of the newly merged company ordain furnish the welcome and introduction. EskoArtwork’s senior product managers will highlight the latest innovations in technology for the Packaging Industry including Dynamic circumscribe for Adobe® Illustrator® workflow automation. JDF act upon proofing and web to print. Guest speaker is Marcus Lynch of Adobe®. There will also be an ArtiosCAD user assort break-out session.

Forex Groups - Tips on Trading

Related article:
http://www.esko.com/web/site.aspx?p=54&PressReleaseID=1538

comments | Add comment | Report as Spam

EskoArtwork the worldwide market leader with pre-production and collaboration software for packaging buyers designers and manufacturers is to hold its annual seminar for packaging professionals on the 29th November from 10am – 4.45pm. It has been a busy year in the Packaging Industry especially for Esko and Artwork Systems as they merged into one organization with one vision. Around 150 packaging companies have accepted the invitation to be this popular event held this year at Nottingham University’s Conference Centre. Guido Van der Schueren. Chief Commercial Officer of the newly merged affiliate will furnish the welcome and introduction. EskoArtwork’s senior product managers will highlight the latest innovations in technology for the Packaging Industry including Dynamic Content for Adobe® Illustrator® workflow automation. JDF colour proofing and web to print. Guest speaker is Marcus Lynch of Adobe®. There will also be an ArtiosCAD user assort break-out session.

Forex Groups - Tips on Trading

Related article:
http://www.esko.com/web/site.aspx?p=54&PressReleaseID=1538

comments | Add comment | Report as Spam

About 120 researchers from the Nano2Life (N2L) network are expected to be the annual meeting held in chewéry/Switzerland between 9–11 January 2008. The meeting ordain act place in “Le Palladium de chewéry�. The meeting ordain furnish excellent opportunities to hit the books about the various initiatives launched by the N2L consortium to hear about challenging topics to present scientific research to communicate with the European N2L community to create new projects and to learn about the latest news in nanobiotechnology. Representatives from bionano start-up's and industries from Switzerland are expected to act in these activities which are organised by the Fondation Suisse pour la Recherche en Microtechnique and the Ecole Polytechnique Fédérale in Lausanne. Founded in 2004. N2L the first European Commission-supported network of excellence in nanobiotechnology (NBT) comprises 23 major European organisations and associated industrial companies from the handle of nanobiotechnology. N2L is the most active European communicate in NBT and has become the visible face of NBT in Europe.

Forex Groups - Tips on Trading

Related article:
http://www.alphagalileo.org/index.cfm?_rss=1&fuseaction=readevent&eventid=525414

comments | Add comment | Report as Spam

I am Fred WIlson. This is my tumblog. I try to affix a quote a song and a conceive of of me every day. Some days I actually do that. I also pull in links to everything else I do on the web to this tumblog. And I reblog the things I find on tumblr that I like. I wish you enjoy your visit.

Forex Groups - Tips on Trading

Related article:
http://fredwilson.vc/post/20336058

comments | Add comment | Report as Spam

SAN DIEGO--(BUSINESS WIRE)--Nov 26. 2007 - Nereus Pharmaceuticals,Inc. a pioneer in the use of marine microbial sources for thediscovery and development of cancer therapeutics and itscollaborators ordain present preclinical study results involving itscancer drug candidate NPI-0052 at the 49th Annual Meeting of theAmerican Society of Hematology (ASH) in Atlanta. Georgia December8-11. Two oral presentations and two posters ordain highlight thenovel mechanism high potency and synergistic anti-tumor activityof the small molecule proteasome inhibitor NPI-0052 in combinationwith bortezomib (Velcade(TM). Millennium Pharmaceuticals) inseveral tumor models for multiple myeloma. Waldenstrom'smacroglobulinemia and B-non-Hodgkin's lymphoma. The findingsillustrate how the two proteasome inhibitors affect the aim toproduce significantly different efficacy and toxicologycharacteristics in preclinical studies. In addition early safetydata from Nereus' arrange I dose escalation trial of NPI-0052 inpatients with lymphomas and solid tumors will be published in ASH'sabstract air of daub. In addition to the preclinical and clinical data for NPI-0052 tobe presented at ASH a cover co-authored by Nereus' ChiefTechnology Officer and Scientific Co-founder Michael Palladino,Ph. D with collaborators from the Dana-Farber Cancer initiate hasbeen accepted for publication in a future edition of ASH's Blood. The investigate again demonstrates that combining NPI-0052 andbortezomib induces synergistic anti-multiple myeloma activity in anumber of preclinical models. Aldo Roccaro. Xavier Leleu. Antonio Sacco. Xiaoying Jia,Anne-Sophie Moreau. Hai Ngo. Abdelkareem Azab. Feda Azab. EvdoxiaHatjiharissi. Steven Treon. Teru Hideshima. Michael Palladino,Kenneth Anderson. Dharminder Chuahan. Irene Ghobrial. Dana-FarberCancer initiate. Boston. MA. Nereus Pharmaceuticals. San Diego,CA. Dharminder Chauhan. Ajita Singh. Mohan Brahmandam. Klaus Podar,Teru Hideshima. Robert Schlossman. Paul Richardson. Nikhil Munshi,Michael Palladino. Kenneth C. Anderson. Dana-Farber CancerInstitute. Boston. MA; Nereus Pharmaceuticals. San Diego. CA. #667 - Targeting Cdk4/6 in combination therapy overcomesproteasome inhibitor resistance in multiple myeloma throughsynergistic mitochondria depolarization Xiangao Huang. Tracey Louie. Maurizio Di Liberto. Jun Rice,David Jayabalan. Kang Zhang. Michael Palladino. Isan Chen. PeterToogood. Ruben Niesvizky. Malcolm A. S. Moore. Selina Chen-Kiang. Departments of Pathology and Medicine and have Program inImmunology and Microbial Pathogenesis. Weill Cornell MedicalCollege. New York. NY. Memorial Sloan-Kettering Cancer Center. NewYork. NY. Nereus Pharmaceuticals. San Diego. CA. Pfizer GlobalResearch and Development. San Diego. CA and Ann Arbor. MI. Stavroula Baritaki. Kam Yeung. Devasis Chatterjee. MichelPalladino. Benjamin Bonavida. Departments of Microbiology,Immunology and Molecular Genetics. David Geffen School of care for,Johnson Comprehensive Cancer bear on. UCLA. Los Angeles. CA;Biochemistry and Molecular Biology. Medical College of Ohio,Toledo. OH; care for. Brown University and Rhode Island Hospital,Providence. RI; Nereus Pharmaceuticals. San Diego. CA. Razelle Kurzrock. Paul Hamlin. Anas Younes. David Hong. MichaelGordon. Matthew A. Spear. Michael A. Palladino. G. Kenneth Lloyd,Angie M. Longenecker. Saskia T. C. Neuteboom. Gillian F. Cropp,Alison Hannah. sing Aghajanian (Intr by Alison L. Hannah). M. D. Anderson Cancer bear on. Houston. TX. Memorial Sloan-KetteringCancer Center. New York. NY. Premiere Oncology of Arizona,Scottsdale. AZ. Nereus Pharmaceuticals. San Diego. CA. Nereus' novel small molecule proteasome inhibitor NPI-0052 isin three Phase I trials at world-class cancer centers in the U. S.,Australia and Europe for solid tumors lymphomas leukemias andmultiple myeloma. Clinical trial sites consider the M. D. AndersonCancer Center the Memorial Sloan-Kettering Cancer bear on theDana-Farber Cancer Institute. Ohio State University. Roswell ParkCancer Institute and University of Chicago. Preclinical studiesindicate that this next generation compound may be superior toother proteasome inhibitors with broader aim inhibition fasteronset and longer duration of action higher potency oral andintravenous availability and activity against myeloma cellsresistant to Velcade. Thalomid(R) (thalidomide. CelgeneCorporation). Revlimid(R) (lenalidomide. Celgene Corporation) andsteroid therapy. NPI-0052 was derived from a marine-obligategram-positive actinomycete (Salinispora tropica). Nereus Pharmaceuticals pursues novel sources of chemicaldiversity to sight and develop new therapeutics. Using itsunmatched expertise in marine microbiology to determine uniquebiologically active compounds the Company has two oncology drugcandidates in Phase I clinical trials. NPI-2358 a tumor vasculardisrupting agent is being evaluated in patients with solid tumorsand lymphomas and the proteasome inhibitor NPI-0052 is beingdeveloped in patients with solid tumors lymphomas leukemias andmultiple myeloma. The Company's discovery portfolio also includespotential drug candidates for cancer infectious diseases andinflammation. For more information visit www nereuspharm com. Nereus Pharmaceuticals is a registered trademark of NereusPharmaceuticals. Inc. All other product and affiliate names may beregistered trademark or trademarks of their respective owners.

Forex Groups - Tips on Trading

Related article:
http://feeds.drugs.com/~r/Drugscom-ClinicalTrials/~3/190725254/nereus-pharmaceuticals-present-research-annual-meeting-american-society-hematology-2770.html

comments | Add comment | Report as Spam

forwarded info on another competition to me from the : From the :“BJP is calling for entries for our fourth annual International Photography Awards and we are looking for a photographer with a substantial series of images to put on an exhibition at in London’s creative hub. Shoreditch. The winner will benefit from a bespoke function - from printing the exhibition to th opening night open - to showcase their work to images buyers and the public at large.” Last year’s winner was whose first schedule “Welcome to Pyongyang” was recently published by […] [Imaging Insider Comment: Here’s a third from the BJP International Photography allocate that was caught by Mary Virginia Swanson. Read More…] […]

Forex Groups - Tips on Trading

Related article:
http://marketingphotos.wordpress.com/2007/09/14/4th-annual-the-bjp-international-photography-award-deadline-92407/

comments | Add comment | Report as Spam

ISPE ordain show the latest in technical education case studies and real world industry-impacting information for the pharmaceutical manufacturing industry at its 2007 Annual Meeting at Caesars Palace in Las Vegas. Nevada. U. S.. November 4-7. ISPE — a global not-for-profit Society representing 25,000 Members — presents this premier event for professionals to act with industry visionaries and be active participants in shaping the future of pharmaceutical manufacturing and biotechnology. "Delivering Today. Transforming Tomorrow" will focus on delivering what’s new current and relevant to the industry focusing on fundamentals beat practices transformation and innovation. More than 40 sessions — including regulatory workshops — ordain give information and interaction on Product Quality Lifecycle Implementation (PQLI) personalized medicine technology assign nanotechnology real world project management disposables latest trends in laboratory design and three newly-released ISPE technical documents. set speakers ordain show timely and compelling topics on the cost of quality perspective from another industry and an insider’s believe of a generic facility. Charlie Portwood. President of Wyeth’s Technical Operations and Product Supply (TO&PS) organization ordain address the Importance of Integrating Standardized Systems in Quality Manufacturing. Gary Convis. Chairman of Toyota go Manufacturing Kentucky and Executive Vice President of Toyota Mort Engineering and Manufacturing North America ordain discuss the role of management in lean manufacturing along with its commitment to a "customer first" philosophy; and Uri Boneh. Director of Global Engineering for Teva Global Generic Resources will speak about Teva’s Jerusalem oral solid dosage plant recently completed and approved by the US Food and Drug Administration. New to the 2007 ISPE Annual Meeting sessions ordain be organized by seven tracks to back up attendees choose the events that beat meet their needs or allow them to cross-train in areas of arouse outside their fields. Tracks include: The regulatory bring in will include three sessions on PQLI on 5-6 November and bring together regulators from all three ICH regions — European Medicines Agency (EMEA). U. S. Food and Drug Administration (FDA) and the Ministry of Labor and Human Welfare (MLHW) — and the respective industry trade organizations from those three regions. This rich schedule will offer delegates the opportunity to overlap their expertise with the regulators who will be there to comprehend to the industry in order to begin to define areas where industry ordain be able to give technical framework for the implementation ICH documents and back up fashion a pragmatic approach to implementing the Q8. Q9 and ultimately Q10 guidances. These sessions ordain create on the foundation created in Washington in June; ordain create on the Berlin Conference to be held in September; and will be the basis to help create the agenda for Copenhagen. Denmark in April 2008. Facility of the Year allocate: In addition to the educational offerings the overall 2007 Facility of the Year Award winner will be announced for the first time. Category winners for 2007 were create from raw material Pharmica of Bloomington. Indiana. U. S.; Genentech of Ocean City. California. U. S.; abduct Roche Pharmaceuticals. Ltd. of Shanghai. China; Taiyo Pharmaceutical Industry Co.. Ltd. of Takayama City. lacquer; and Vetter Pharma-Fertigung GmbH & Co. KG of Ravensburg. Germany. Representatives from those companies ordain be on transfer and one ordain be named overall FOYA winner and awarded a stunning crystal trophy. For more information visit ISPE Membership and Awards Ceremony ordain be held 6 November and reveal the winners of the ISPE Member of the Year. Company of the Year. Chapter or interact of the Year. International Student Poster Competition winner among many others. Certified Pharmaceutical Industry Professional (CPIP) workshops will be held 5-7 November to give information about this program and examination overview. For more information gratify visit Communities of Practices ordain feature roundtable events for develop specific exchanges of ideas and beat practices. 4 November. For more information on COPs please visit delay Top Exhibition ordain be held 4-6 November to showcase products and services from the industry. For information communicate Dave Hall at +1-813-960-2105 or dhall@ISPE org or tour About ISPEISPE the International Society for Pharmaceutical Engineering is the Society of choice for 25,000 pharmaceutical manufacturing professionals in 90 countries around the globe. ISPE aims to be the catalyst for "Engineering Pharmaceutical Innovation" by providing Members with opportunities to develop technical knowledge exchange practical experience and work with global regulatory agencies and industry leaders. Founded in 1980. ISPE has worldwide headquarters in Tampa. Florida. U. S.; its European office in Brussels. Belgium; and its Asia Pacific office in Singapore. Visit for additional Society news and information.

Forex Groups - Tips on Trading

Related article:
http://www.pharmaceuticalonline.com/content/news/article.asp?docid=0bca2c53-bf89-4232-b08a-9955503f7bd1&atc~c=771+s=773+r=001+l=a

comments | Add comment | Report as Spam